Glaxosmithkline Pharmaceuticals Ltd Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Consolidate Quarterly Results

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Net Sales

1,041.26

979.94

805.17

974.37

949.42

1,010.77

814.65

Other Operating Income

0.00

Total Operating income

1,041.26

979.94

805.17

974.37

949.42

1,010.77

814.65

Raw Material Cost

79.90

115.13

128.06

115.23

97.48

148.96

138.23

Purchase of Finished goods

217.27

232.72

232.06

291.40

164.23

216.74

172.74

(Increase) / Decrease In Stocks

66.65

7.68

-72.41

-54.69

97.45

18.79

-15.70

Employee Cost

151.88

138.05

152.57

152.97

124.74

150.71

151.28

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

154.22

150.63

113.69

136.27

173.60

153.86

137.56

Total Expenditure (Excl Depreciation)

669.92

644.21

553.97

641.18

657.50

689.06

584.11

Operating Profit (PBDIT) excl Other Income

371.34

335.73

251.20

333.19

291.92

321.71

230.54

Other Income

32.12

33.57

43.72

40.68

35.07

34.54

35.64

Operating Profit (PBDIT)

403.46

369.30

294.92

373.87

326.99

356.25

266.18

Interest

1.19

0.51

0.42

0.58

0.09

0.27

0.37

Exceptional Items

17.98

2.64

0.00

4.69

0.00

Gross Profit (PBDT)

420.25

371.43

294.50

373.29

326.90

360.67

265.81

Depreciation

20.32

17.43

15.52

14.72

18.80

16.86

16.41

Profit Before Tax

399.93

354.00

278.98

358.57

308.10

343.81

249.40

Tax

104.31

96.51

73.97

95.70

78.22

91.31

67.07

Provisions and contingencies

0.00

Profit After Tax

295.62

257.49

205.01

262.87

229.88

252.50

182.33

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

295.62

257.49

205.01

262.87

229.88

252.50

182.33

Share in Profit of Associates

0.00

Minority Interest

0.00

Other related items

0.00

Consolidated Net Profit

295.62

257.49

205.01

262.87

229.88

252.50

182.33

Equity Capital

169.41

Face Value

10.0

Reserves

0.00

Earnings per share (EPS)

17.45

15.2

12.1

15.52

13.57

14.9

10.76

Diluted Earnings per share

17.45

15.02

12.1

15.52

13.57

14.91

10.76

Operating Profit Margin (Excl OI)

35.66%

34.26%

31.2%

34.2%

30.75%

31.83%

28.3%

Gross Profit Margin

40.36%

37.9%

36.58%

38.31%

34.43%

35.68%

32.63%

PAT Margin

28.39%

26.28%

25.46%

26.98%

24.21%

24.98%

22.38%

Public Share Holdings (%)

0.0%

Pledged Promotor Holding (%)

0.0%

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Dec 2025 is 6.26% vs 21.71% in Sep 2025

Consolidate Net Profit

QoQ Growth in quarter ended Dec 2025 is 14.81% vs 25.60% in Sep 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Dec 2025 is 10.61% vs 33.65% in Sep 2025

Interest

QoQ Growth in quarter ended Dec 2025 is 133.33% vs 21.43% in Sep 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Dec 2025 has improved from Sep 2025

Compare Quarterly Results Of Glaxosmi. Pharma With

Select Peers

Figures in Cr

Consolidate Quarterly Results

Change(INR)

Change(%)

Net Sales

1,041.26

1,778.29

-737.03

-41.45%

Other Operating Income

0.00

Total Operating income

1,041.26

1,778.29

-737.03

-41.45%

Raw Material Cost

79.90

725.32

-645.42

-88.98%

Purchase of Finished goods

217.27

55.12

162.15

294.18%

(Increase) / Decrease In Stocks

66.65

-85.87

152.52

177.62%

Employee Cost

151.88

229.24

-77.36

-33.75%

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

154.22

374.27

-220.05

-58.79%

Total Expenditure (Excl Depreciation)

669.92

1,298.08

-628.16

-48.39%

Operating Profit (PBDIT) excl Other Income

371.34

480.21

-108.87

-22.67%

Other Income

32.12

5.76

26.36

457.64%

Operating Profit (PBDIT)

403.46

485.97

-82.51

-16.98%

Interest

1.19

38.79

-37.60

-96.93%

Exceptional Items

17.98

0.00

17.98

Gross Profit (PBDT)

420.25

447.18

-26.93

-6.02%

Depreciation

20.32

120.62

-100.30

-83.15%

Profit Before Tax

399.93

326.56

73.37

22.47%

Tax

104.31

73.45

30.86

42.01%

Provisions and contingencies

0.00

Profit After Tax

295.62

253.11

42.51

16.80%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

295.62

253.11

42.51

16.80%

Share in Profit of Associates

0.00

-1.23

1.23

100.00%

Minority Interest

0.00

0.22

-0.22

-100.00%

Other related items

0.00

Consolidated Net Profit

295.62

251.66

43.96

17.47%

Equity Capital

169.41

107.97

61.44

56.90%

Face Value

10.00

2.00

0.00

Reserves

0.00

Earnings per share (EPS)

17.45

4.66

12.79

274.46%

Diluted Earnings per share

17.45

4.65

12.80

275.27%

Operating Profit Margin (Excl OI)

35.66%

27.00%

0.00

8.66%

Gross Profit Margin

40.36%

25.15%

0.00

15.21%

PAT Margin

28.39%

14.23%

0.00

14.16%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 1,041.26 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is 6.26% vs 21.71% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 9.67% vs 17.90% in Dec 2024

Quarterly - Consolidate Net Profit

Consolidate Net Profit 295.62 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is 14.81% vs 25.60% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 28.60% vs 402.80% in Dec 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 371.34 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is 10.61% vs 33.65% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 27.21% vs 33.87% in Dec 2024

Quarterly - Interest

Interest 1.19 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is 133.33% vs 21.43% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 1,222.22% vs -71.88% in Dec 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 35.66%

in Dec 2025

Figures in %

QoQ Growth in quarter ended Dec 2025 has improved from Sep 2025

YoY Growth in quarter ended Dec 2025 has improved from Dec 2024